机译:HER2阳性乳腺癌患者的新型治疗策略,不会受益于目前靶向治疗药物的患者
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
Peking Univ Dept Hepatol Hlth Sci Ctr Teaching Hosp 302 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
Anhui Med Univ PLA Clin Hosp 306 Dept Gen Surg Beijing 230000 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Pathol Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
306 Hosp PLA Dept Gen Surg An Xiang Bei Li 9 Beijing 100101 Peoples R China;
HER2 target therapy; trastuzumab; neratinib; drug resistance; targeted delivery drugs; natural anti-cancer substances;
机译:HER2阳性乳腺癌患者的新型治疗策略,不会受益于目前靶向治疗药物的患者
机译:基于靶寡核苷酸的癌症疗法的目前发育:对HER2阳性乳腺癌治疗的透视
机译:HER2靶向疗法对转移性HER2阳性乳腺癌患者总体生存的益处-系统评价
机译:乳腺MRI辐射射清,用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
机译:在 中美 关于 药物 治疗依从性 和非药物 医疗利用 成本控制策略 的影响 和 成本 在 乳腺癌患者
机译:无法从当前靶向治疗药物中受益的HER2阳性乳腺癌患者的新治疗策略
机译:基于靶寡核苷酸的癌症疗法的目前发育:对HER2阳性乳腺癌治疗的透视